JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - DENALI THERAPEUTICS INC
Financial Performance:
- U.S. Hunter Syndrome (MPS II) launch is described as "very successful" with strong community uptake.
- Annual pricing in the U.S. for a 30kg patient is approximately $800,000, representing a ~60% premium over the incumbent Elaprase ($500,000).
- Q4 2025 revenue guidance is provided for the first time, set at $30–32 million.
- Management confirmed quarterly revenue guidance will be provided for 2026 to clarify launch trajectory; 2027 guidance is not yet disclosed.
- Revenue generation from Avlea extends the company's cash runway.
- No specific figures on total cash, debt, or margins were disclosed in this transcript.
Guidance and Future Outlook:
- BLA filing for Sanfilippo Syndrome (MPS III) expected in 2026.
- Key data readouts scheduled for:
- COMPAS study (Head-to-head vs. Elaprase in Hunter Syndrome): End of 2026 for two-year endpoints, with potential market access in 2028.
- Sanfilippo Phase 2 full dataset (20 patients): World Molecular Medicine meeting in February 2027.
- Progranulin (FTD) dataset: First half of 2027.
- Alzheimer's Tau and Beta-amyloid (DNL921) early biomarker data: 2027.
- Long-term goal is to expand Avlea label to include adults (currently 25% of the population, >30% of value) and secure international approvals.
- Management aims to become the market leader in Hunter Syndrome, treating all new patients and capturing significant share from existing ERT users.
Business Segments and Product Lines:
- Avlea (Hunter Syndrome): The first commercial product; utilizes the transport vehicle platform to cross the blood-brain barrier (BBB). Currently approved for pediatric patients; seeking adult expansion.
- Sanfilippo (MPS III): Enzyme transport vehicle candidate; early data shows 80% reduction in CSF heparan sulfate and normalization in a subset of patients. Confirmatory Phase 3 study design is being finalized, potentially leveraging historical controls following recent gene therapy approvals.
- Progranulin (FTD): Protein replacement therapy for Granulin mutation FTD; treatment duration extended from 6 to 12 months to capture neurofilament light chain (NFL) biomarker changes.
- Alzheimer's Portfolio:
- Tau (DNL921): IV delivery using transport vehicle for even brain distribution; targeting >20-50% CSF tau reduction.
- Beta-amyloid: Uniquely engineered antibody with "on-off switch" mechanism to minimize immunogenicity and hematological side effects (reticulocytes); aiming for sub-Q dosing.
- Pompe Disease: Mentioned as an important readout in the pipeline.
Market and Competitive Landscape:
- Hunter Syndrome: Addressable U.S. population is ~375 patients (75% of total ~500) under current label; global population estimated at ~2,000. Incumbent Elaprase generates ~$700M globally; Denali expects to exceed this total.
- Competitive Advantage: Avlea's BBB penetration and superior biomarker reduction (heparan sulfate) vs. Elaprase's lack of CNS efficacy.
- Alzheimer's: Differentiation lies in the transport vehicle technology enabling even brain distribution and sub-Q dosing, contrasting with intrathecal delivery (Biogen) and traditional antibody approaches with hematological risks.
- Regulatory Environment: Shifting landscape with Ultragenyx's gene therapy approval using natural history comparators; Denali actively engaging FDA to align Phase 3 designs for Sanfilippo.
Risks and Challenges:
- Regulatory Hurdles: Need for label expansion into adults and international markets (COMPAS study required for many ex-U.S. regions).
- Clinical Trial Design: Sanfilippo study design must adapt to the new regulatory bar set by recent gene therapy approvals and potential use of historical controls.
- Biomarker Thresholds: Uncertainty regarding the specific magnitude of NFL or tau reduction required for accelerated approval.
- Patient Selection: Critical need to capture Sanfilippo patients early in the disease course before severe progression; heterogeneity in patient mutations and disease progression.
- Competition: Emerging gene therapies and amyloid/tau inhibitors in Alzheimer's.
Management Commentary and Tone:
- Tone is highly confident and enthusiastic, emphasizing the validation of the "transport vehicle" platform.
- Management highlights "overwhelming" positive feedback from patient families and physicians regarding Avlea.
- CEO Ryan Watts and CCO Katie Payne express strong belief that Avlea will become the standard of care and exceed Elaprase revenues.
- CFO Alex Shuth provided precise revenue guidance, signaling a transition to a commercial-stage company.
- Emphasis on the strategic value of the platform's ability to treat both pediatric and adult indications and to reach the brain safely.
Analyst Questions and Answers:
- Pricing vs. Competitor: Confirmed $800k vs. $500k annual cost in U.S.
- Growth Trajectory: Management committed to quarterly guidance for 2026; 2027 guidance pending.
- COMPAS Study Details: 65 patients, two cohorts (neurologic and somatic/adults); head-to-head with Elaprase using Vineland (behavior) and HS biomarker co-primary endpoints.
- Sanfilippo Dosing: Learning that more frequent dosing improves tolerability; 80% biomarker reduction achieved in early cohort.
- Alzheimer's Differentiation: Clarified that IV transport vehicle offers even distribution unlike intrathecal methods, expecting better clinical correlation with CSF biomarkers.
- Sub-Q Dosing: A major strategic goal for Alzheimer's and potentially other programs, though timing specifics were deferred ("stay tuned").
Other Key Points:
- The "transport vehicle" platform is the core value proposition, validated by Avlea and applicable across the entire pipeline (Hunter, Sanfilippo, FTD, Alzheimer's, Pompe).
- The Sanfilippo Phase 2 data presentation will include 20 patients (8 initial + 12 additional), with 12 pre-specified as the to-be-marketed dose cohort.
- Management noted that in FTD, NFL reduction is a strong predictor of clinical benefit, citing Tofersen's ALS approval as precedent.
- The DNL921 Alzheimer's antibody uses an integrated TFR binding mechanism rather than linkers, theoretically improving stability and brain uptake compared to conventional formats.
- Company
- DENALI THERAPEUTICS INC
- Keywords
- DENALI THERAPEUTICS INC